A framework for how environment contributes to cancer risk by Hochberg, M. E. & Noble, R.
              
City, University of London Institutional Repository
Citation: Hochberg, M. E. and Noble, R. ORCID: 0000-0002-8057-4252 (2017). A 
framework for how environment contributes to cancer risk. Ecology Letters, 20(2), pp. 117-
134. doi: 10.1111/ele.12726 
This is the accepted version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  https://openaccess.city.ac.uk/id/eprint/24706/
Link to published version: http://dx.doi.org/10.1111/ele.12726
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
  1 
A framework for how novel environments contribute to cancer risk 
  
Michael E. Hochberg1,2 & Robert J. Noble1 
1 Intstitut des Sciences de l’Evolution de Montpellier, Université de Montpellier, Place E. 
Bataillon, CC065, 34095 Montpellier Cedex 5, France 
2 Santa Fe Institute, 1399 Hyde Park Rd., Santa Fe, NM 87501, USA 
  
  
Type of article: Ideas and Perspectives 
Running title: Novel environments and cancer 
Keywords: Aging, anthropogenic impact, cancer risk, environment, epidemiology, 
evolutionary mismatch, longevity, body size, global change, modern lifestyles, mutagens, 
pathogens 
Statement of authorship: MEH conceived the study, wrote the manuscript, designed the 
figures, and contributed to the figures and boxes; RJN performed the modelling work, 
designed and produced the figures, and contributed to the boxes and revisions. 
Data accessibility statement: We confirm that, should our manuscript be accepted, the data 
supporting our results will be archived in an appropriate public repository. 
Content: Abstract (192 words); Main text (7836 words); 236 References; 1 Glossary; 4 
Figures; 4 Boxes 
Author for correspondence: Michael Hochberg, ISEM - UMR 5554, Université de 
Montpellier, CC065, Place E. Bataillon, 34095 Montpellier Cedex 5, France. Telephone: +33 
4 67143667. Email: mhochber@univ-montp2.fr 
 
 
  2 
Abstract 
Evolutionary theory explains why metazoan species are largely protected against the negative 
fitness effects of cancers. Nevertheless, cancer is often observed at high incidence across a 
range of species. Although there are many challenges to quantifying cancer epidemiology and 
assessing its causes, we claim that most modern-day cancer in animals--and humans in 
particular-- is due to environments deviating from central tendencies of distributions that 
have prevailed during cancer resistance evolution. Such novel environmental conditions may 
be natural and/or of anthropogenic origin, and may interface with cancer risk in numerous 
ways, broadly classifiable as those: increasing organism body size and/or life span, disrupting 
processes within the organism, and changing germline. We argue that anthropogenic 
influences, in particular, explain much of the present-day cancer risk across life, including in 
humans. Based on a literature survey of animal species and a parameterized mathematical 
model for humans, we suggest that combined risks of all cancers in a population beyond c. 
5% can almost invariably be explained by the influence of novel environments. Our 
framework provides a basis for understanding how natural environmental variation and 
human activity impact cancer risk, with potential implications for species ecology. 
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Introduction 
Cancer is a pervasive threat to many multicellular organisms, and vulnerable populations are 
expected to evolve cancer prevention and suppression (hereafter ‘resistance’). Indeed, a large 
array of resistance mechanisms exist, including tissue architecture, cell cycle regulation and 
differentiation, DNA mismatch repair, apoptosis, immune responses, and replicative aging 
(Greaves 2000; DeGregori 2011; Reinhardt and Schumacher 2012; Campisi 2013). Despite 
the likely deep evolutionary history in the establishment and reinforcement of these 
processes, cancers occur across the tree of life, and sometimes at high incidence (Aktipis et 
al. 2015). These contradictory observations beg for explanation, specifically regarding the 
role of environments in promoting or suppressing cancer, and the implications of dynamic 
cancer risks for species ecology and evolution. 
Much of our understanding of cancer comes from human tumour cells, either isolated de novo 
from biopsies, or studied on well characterized cell lines in vitro, or as allografts in 
immunodeficient laboratory mice. Only recently has increased emphasis been given to 
investigating cancers over a broad range of taxa (comparative oncology, see Glossary, 
(Schiffman et al. 2015; Nunney et al. 2015)). Although our knowledge remains largely 
restricted to humans, most cancers are thought to emerge through a stepwise mutational 
process, resulting in the Hallmarks of Cancer (Hanahan and Weinberg 2000; Hanahan and 
Weinberg 2011). A central prediction of the multistage theory of carcinogenesis (Glossary) is 
that, all else being equal, lifetime risk of any form of cancer (hereafter ‘cancer risk’; 
Glossary) should correlate with the lifetime number of stem cell divisions (Box 1). Perhaps 
surprisingly, cancer risk across mammal species shows no significant trend with longevity or 
with body mass (Peto et al. 1975; Peto 1977). There are numerous explanations for what has 
come to be known as Peto’s paradox (Glossary) (e.g., (Nunney 1999; Leroi et al. 2003; Nagy 
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et al. 2007; Caulin and Maley 2011; DeGregori 2011; Nunney 2013; Maciak and Michalak 
2015)), most being based on differential selection for phenotypic traits that reduce cancer risk 
in more massive and/or longer-lived species. 
Whereas considerable study addresses Peto’s paradox, few authors have recognized an 
additional feature of the cancer risk data: most surveyed species and taxonomic groups have 
lifetime cancer risks of less than c. 5%, and for many, cancer is very rarely observed, if at all 
(e.g., (Effron et al. 1977; Varki 2000; Abegglen et al. 2015)). To the best of our knowledge 
and when sufficiently investigated, high lifetime cancer risk (conservatively defined here as 
greater than c. 5% of a population suffering cancer-related negative effects on performance, 
health, survival, and/or fitness during their lifetimes) is observed only in populations that live 
in captivity or in polluted areas, or that are subject to cancer-promoting infections, founder 
effects, inbreeding, or selective breeding. Even in the human population where cancers 
account for c. 11-25% of mortality (Ferlay et al. 2015), and as will be described below, the 
majority of cases are associated with present-day human ecology, including survival to older 
ages, modern lifestyles, parasitic infections, and mutagenic exposure. 
Previous study has discussed how evolutionarily novel environments (Glossary) are a likely 
source of many human diseases (Gluckman and Hanson 2004; Gluckman et al. 2011), and 
associations between environments and cancer across species (e.g., (Newman and Smith 
2006; McAloose and Newton 2009)) and in humans (Irigaray et al. 2007). We go 
significantly beyond these by proposing a framework for how environments, and specifically 
novel environments, affect cancer risk across species and in the human population. We argue 
that many, probably most cancers across animal species, and particularly in humans, result 
from environmental states that increase cancer risk above baseline levels occurring in native 
habitats (Figure 1). These baseline levels reflect long-term adaptations to prevailing 
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exogenous (e.g., temperature, physical habitat and biotic interactions) and endogenous (e.g., 
behaviour and physiology) environmental conditions. Environments obviously vary over 
different spatial and temporal scales, and evolutionary theory predicts how a species adapts to 
varying selection pressures (e.g., (Chevin et al. 2010; Tuomainen and Candolin 2011)). 
Importantly, trait evolution can be slow relative to the time scales of environmental variation 
and behavioural responses (Tuomainen and Candolin 2011), meaning that the absolute fitness 
associated with a trait may vary considerably without a significant evolutionary response (so 
called “evolutionary mismatches”). This is particularly relevant to cancers, where specific 
costly adaptations are unlikely to obtain in response to the diversity of possible transient and 
spatially limited environmental insults. Moreover, due to the complexity of cancer genetics 
(Blekhman et al. 2008; Hindorff et al. 2011), and weak selection against certain cancer 
sensitivity mutations (Frank 2004a), the fixation of resistance across all cancer-risk loci is 
unlikely, even in the long term (Maher et al. 2013). 
Deviations from native habitat conditions may take the form of idiosyncratic pulses, 
sustained temporal variation, directional trends, or shifts to new states. Given heterogeneity at 
different spatial and temporal scales, environmental exposure and associated cancer risk are 
expected to vary within a population. Although it is difficult to accurately estimate baseline 
cancer risks and the environments under which these prevailed, we can identify putative 
environmental drivers of increased risk by focussing on species (or populations) showing 
unexpectedly high overall levels of cancer (i.e., greater than the conservative benchmark 
level of 5%). Humans have influenced ecosystems since the Late Pleistocene (Boivin et al. 
2016), and we claim that as a result of the intensification and globalization of these effects, 
the environments experienced by many present-day metazoan species differ significantly 
from their pre-anthropogenic states (Eriksson 2013), and consequently many, possibly most 
instances of high cancer risk are attributable to human impacts. 
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We begin by reviewing the theoretical and empirical basis for how evolutionary adaptations 
limit cancer as a life threatening and fitness reducing disease. This sets the stage for 
understanding how environmental deviations from native conditions, typically acting on 
shorter time scales than significant evolutionary responses, affect individual biology and 
ecology, which in turn, impacts individual cancer risks. There are nevertheless numerous 
hurdles in quantifying cancer epidemiology and assessing relationships between environment 
and cancer, and we discuss five such limitations. We then present a framework where novel 
environments impact cancer risk via one or more of three basic biological levels: those 
increasing body size and/or longevity, those disrupting within-organism processes, and those 
resulting in heritable genetic change. We finally develop and analyse an empirically 
parameterized mathematical model to deduce overall cancer incidence in recent and ancient 
humans, which also allows estimation of how different components of modern (novel) 
environments have increased cancer risk in our species. Our framework provides a basis for 
understanding the relevance of environments to cancer across life, uncovers a number of 
important questions regarding the implications of cancer dynamics for ecological 
communities and evolutionary change, and makes predictions for future research. 
  
The evolutionary theory of cancer resistance 
Somatic cells in metazoans exhibit an array of cooperative behaviours that contribute to the 
fitness of the whole organism. Obtaining the benefits of cooperation without paying the costs 
would have provided the context for cells to effectively cheat (Glossary). Cancer is a prime 
example of cheating in the metazoa (Aktipis et al. 2015), whereby somatic cells grow and 
invade local and distant tissues (invasive carcinoma and metastasis, respectively). Failure of 
higher-level physiological systems to prevent this process or keep it in check would have had 
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substantial fitness consequences for the host organism, resulting in selection for costly cancer 
resistance mechanisms (Crespi and Summers 2005; Merlo et al. 2006; Casás-Selves and 
Degregori 2011; Greaves and Maley 2012; Aktipis et al. 2015). The evolution of some of 
these processes appears to have occurred deep in the metazoan phylogeny, where cancer risk 
and its reduction were associated with the emergence of “gatekeeper” genes (Domazet-Loso 
and Tautz 2010), possibly accompanied (and followed) by purifying selection against cancer-
prone genotypes (Thomas et al. 2003) (but see (Blekhman et al. 2008)). With subsequent 
selection for larger body plans and longer life spans, additional, sometimes apparently 
species-specific, mechanisms have emerged (Gorbunova et al. 2014). 
The evolutionary theory of cancer resistance makes two central predictions. First, taxonomic-
group or species-specific cancer suppression has evolved in response to environmental 
challenges (e.g., UV radiation, temperature, diet, and exposure to competitors, predators and 
parasites) and coevolved with metabolic processes, mutation rates, characteristics of tissue 
and organ microenvironments (Glossary), and life history traits such as body size and life 
span. Theory suggests that if there is positive selection acting on traits that also render 
individuals more susceptible to disease, then the positive trait is more likely to evolve if the 
marginal costs of augmented disease (cancer) resistance are sufficiently low (Hochberg et al. 
1992; Boddy et al. 2015; Kokko and Hochberg 2015). 
Most empirical support for this first prediction comes from studies on the body size or 
longevity extremes that generate Peto’s paradox. For example, carcinoma in long-lived 
captive naked mole rats has been observed in only a few individuals out of thousands 
examined (Buffenstein 2008; Taylor et al. 2016; Delaney et al. 2016), and it remains to be 
determined whether inbreeding or laboratory conditions may have contributed to these cases, 
which were exclusively middle-aged and older individuals. Study indicates that this species 
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has reinforced resistance against various diseases, including cancers (e.g., (Tian et al. 2013)), 
and that occasional cancer may have both an evolutionary and ecological basis (Hochberg et 
al. 2016). Other work on captive African and Asian elephants reveals that they have 20 
copies of the TP53 tumour suppressor gene, suggesting that the total stem cell population in 
an elephant can tolerate numerous mutations with little risk of any single stem cell lineage 
transforming into a fitness-threatening neoplasm (Abegglen et al. 2015; Sulak et al. 2016). 
Lifetime cancer risk in captive elephants is estimated at 3-5% (Elephant Encyclopedia 1995-
2012. www.elephant.se) (Abegglen et al. 2015). 
Although the evolutionary theory of cancer resistance is consistent with observations of low 
incidence across species and with reinforced protective mechanisms in those species that tend 
to generate Peto’s paradox (i.e., the most massive and longest lived; (Seluanov et al. 2009; 
Gorbunova et al. 2014; Abegglen et al. 2015; MacRae et al. 2015), but see e.g., (Rozhok and 
DeGregori 2016)), complementary approaches such as phylogenetic analyses are uncommon 
(Gomes et al. 2011; Keane et al. 2015). For example, Gomes and colleagues (Gomes et al. 
2011) compared and contrasted telomere length and telomerase activity across more than 60 
mammal species. They propose that the capacity of ancestral adult mammals to suppress 
telomerase has been lost in certain short-lived, small mammal species. Their results are 
consistent with the prediction that replicative aging (shorter telomeres and repressed 
telomerase activity) tends to protect the organism from the fitness-reducing effects of cancer 
as a correlated response to larger body sizes and longer life spans (Weinstein and Ciszek 
2002) (but see (Seluanov et al. 2007; Eisenberg 2011)). 
The second prediction of evolutionary theory is that, whereas no correlation is expected 
between species over the full range of metazoan taxa, variation within a species should reveal 
positive associations between life history traits (particularly longevity) and cancer risk (Box 
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1). This is because selection on life history - cancer resistance tradeoffs is expected to be too 
weak (due, for example, to cancer emerging late in life) over ecological time scales of a few 
generations or less, or there is simply little or no additive genetic variation upon which 
selection can work. Limited support for this prediction comes from the correlation of cancer 
incidence with body mass across dog breeds (Fleming et al. 2011) and with human height 
(Shors et al. 2001; Green et al. 2011; Kabat et al. 2014; Jiang et al. 2015). An alternative, 
untested explanation for these patterns is that life history traits are in linkage disequilibrium 
with specific mutations increasing (or decreasing) cancer risk. 
Similar to body size within a species, cancer incidence and mortality tend to correlate with 
age (in humans (Martincorena and Campbell 2015); in dogs (Fleming et al. 2011); but see (Li 
et al. 1996; Pompei and Wilson 2001)). This is not surprising since classic theory of the 
evolution of aging and senescence (Medawar 1952; Williams 1957; Hamilton 1966) leads to 
the prediction that cancer resistance will be generally favoured in an inverse age-dependent 
manner (e.g., (DeGregori 2011; Hochberg et al. 2013)), but this effect (increasing cancer risk 
for longer lived individuals within a species) is also predicted to be a straightforward 
consequence of more time for (multistage) cancer to obtain, and for emerging tumours to 
grow and constitute risks to individual performance and survival. Another explanation for 
within-species patterns is that cancer risk is somehow pleiotropically associated with 
genetically heritable differences in height or longevity (e.g., (Cournil and Kirkwood 2001)), 
although we are not aware of any supporting evidence. 
  
Challenges to how we perceive and quantify cancer 
Despite a plethora of anecdotal observations of cancer in animals and, more rarely, 
epidemiological studies in natural populations, the actual importance of cancers (altered 
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behaviours, reduced reproduction, synergisms with other diseases, morbidity, mortality) to 
demography, population dynamics, intra- and interspecific interactions, spatial distributions, 
and/or genomic evolution has seldom been demonstrated for any species in the wild[1]. When 
cancer is assessed on wild animals, it is usually semi-quantitative, recorded from individuals 
in captivity (Ratcliffe 1933), and/or typically for only one sampled population at a single time 
point (but see (Lair et al. 2015)). 
We present five non-mutually exclusive factors that limit our ability to accurately assess the 
causes of cancer, and the importance of cancer to the performance, survival or Darwinian 
fitness of the individual, and by extension, the ecological and evolutionary dynamics of 
populations.  
Sampling. Numerous biases exist in interpreting epidemiological data on cancer (e.g., for 
humans see (Doll and Peto 1981)), that also limit our ability to generalize findings about 
cancer in the wild. First and foremost, accurate field sampling in natural, near-pristine 
habitats is highly unusual (McAloose and Newton 2009), and may even be infeasible should 
individuals harbouring a cancer have altered behaviours (Vittecoq et al. 2013; Vittecoq et al. 
2015). In addition, quantification of epidemiological parameters such as incidence, morbidity 
and mortality is potentially biased by (1) small sample sizes (eTable 1 in (Abegglen et al. 
2015)), (2) reports with no follow-up or associated study of hypothetical explanations 
(Daoust et al. 1991), (3) the underreporting of studies revealing little or no observed cancer, 
(4) oversampling of species that are relatively easy to sample and examine (e.g., humans, 
domestic and captive mammals), (5) oversampling of emblematic species (Aguirre and Lutz 
2004), (6) populations suspected to be exposed to carcinogens (Hueper 1963), (7) 
oversampling of species showing unexpectedly high (Lair et al. 2015) or low (Buffenstein 
2008) cancer incidence, (8) oversampling of animals attracting attention through aberrant 
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behaviours, external signs of cancer, or found in atypical locations (e.g., (Newman and Smith 
2006)), and (9) paleopathological analyses indicating high incidence, but that cannot 
accurately ascribe associated health impacts (Nerlich et al. 2006). 
Another form of sampling bias stems from potentially irrelevant phylogenetic and ecological 
comparisons, such as between mice, humans, naked mole rats and whales. A more insightful 
approach is to make comparisons within phylogenetic groups, ecological niches, or life 
histories (Abegglen et al. 2015; Faulkes et al. 2015; Keane et al. 2015; Sanchez et al. 2015). 
Thus, for example, rather than compare mice and naked mole rats, which have little in 
common excepting body size, comparisons should begin within their taxonomic groups, e.g., 
Hystricomorpha (including Heterocephalus glaber) and Myomorpha (including Mus 
musculus). In contrast, some examples of elevated cancer risk in captivity are associated with 
phylogenetically-related taxa (e.g., (Canfield et al. 1990; Owston et al. 2008)), but it is 
unknown to what extent these patterns are related to similar types of environmental forcing, 
similar ecology or biology, or to other, unexplained factors.  
The differences between disease, individual condition, population limitation and natural 
selection. Establishing benchmarks for studying cancer (i.e., simple presence vs. importance 
to the functioning of the host organism) is highly challenging. Even should stem cells obtain 
one or more cancer driver mutations (Glossary), the affected tissue may not become invasive 
(Martincorena et al. 2015), and should a lesion progress to invasive cancer, it may never 
present health (Greaves 2014) or fitness (DeGregori 2011; Hochberg et al. 2013) 
consequences. As with highly virulent microparasitic diseases, the symptoms associated with 
many cancers – especially those producing external tumours – elicit the intuitive reaction that 
they are likely to have individual health and population consequences. However, the severity 
of a disease on individuals does not necessarily predict how the disease will affect population 
size (Anderson 1979), and disease-driven population limitation need not be associated with 
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strong selection for disease resistance (Holt and Hochberg 1997). Rather, the strength of 
selection integrates reduced fitness, allelic dominance (in diploids), the frequency of 
alternative fitter genotypes, and population structure over spatio-temporally heterogeneous 
environments (e.g. (Orr 2009)). 
Cancer emergence, health effects, and fitness consequences are each sequentially 
probabilistic. This means that adaptations to minimize the fitness impacts of cancers should 
increase with extended pre-reproductive and reproductive life spans (Kokko and Hochberg 
2015), but also that cancer will be expressed more often with longer periods of aging and 
senescence, as is the case, for example, in humans (DeGregori 2011; Hochberg et al. 2013). 
Thus, cancer morbidity and mortality at older, post-reproductive ages are generally not 
expected to produce a substantial evolutionary response ( ( (Kirkwood 2005), but see (Brown 
and Aktipis 2015)). Species with short pre-reproductive and reproductive life spans and little 
senescence (e.g., many small mammals and birds (Ricklefs 1998)) will tend to perish before 
succumbing to a threatening neoplasm, and are expected to have less reinforced adaptation to 
preventing cancer. Limited data concur with these basic predictions. For example, elephants 
have long pre-reproductive and reproductive life spans, show little senescence (Promislow 
1991), have reinforced cancer suppression, and their lifetime cancer rates in captivity are less 
than 5% (Abegglen et al. 2015); field mice show high cancer rates, but only when reared 
beyond their short, natural life spans (Andervont and Dunn 1962; Schug et al. 1991; Pompei 
et al. 2001); naked mole rats have long reproductive life spans, show little senescence (e.g., 
Buffenstein 2008), and have reinforced cancer protection (e.g., Tian et al. 2013). 
Real antagonistic pleiotropy? Positive selection on certain phenotypic traits due, for 
example, to antagonistic coevolution may be associated with increased cancer risks (Crespi 
and Summers 2006). Antagonistic pleiotropy (Glossary) is often advanced as an explanation 
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for correlations between positively selected traits and the occurrence of diseases (Carter and 
Nguyen 2011), but evidence for its specific role in cancer is largely indirect, particularly in 
humans (Leroi et al. 2005; Grimes and Chandra 2009; Giaimo and d’Adda di Fagagna 2012). 
For example, studies of human female breast cancers suggest a pleiotropic association 
between fecundity and the presence of BRCA1/2 mutations (Smith et al. 2012; Kwiatkowski 
et al. 2015). Although many factors may be involved, da Silva (da Silva 2012) used 
mathematical models to show that considerable augmentations in fecundity associated with 
weak negative impacts on fitness (resource transfers or the “grandmother effect”; (Croft et al. 
2015; Brown and Aktipis 2015); see also (Pavard and Metcalf 2007)) could explain the 
current low frequencies of BRCA alleles, but only in conjunction with low general female 
fertility in our distant ancestors (by which time much of the evolution leading to the present-
day frequencies would have occurred). Alternatively, the association between BRCA 
mutations and increased fecundity may be real, but not genetically linked. This could occur, 
for example, if there are associations between the mutated BRCA gene and particular ethnic 
groups (Fackenthal and Olopade 2007) or families (Kwiatkowski et al. 2015). 
Perhaps the most convincing evidence for positive selection on a trait linked with cancer 
susceptibility comes from male swordtail fish (Xiphophorus). Hybrid males harbouring the 
Xmrk oncogene are more susceptible to melanomas in later life, but are also larger and better 
at competing for mating opportunities (Fernandez and Morris 2008). Limited evidence comes 
from two additional sources. First, in free-living populations of X. variatus subsequently 
reared in the laboratory, older, non-hybrid males express melanosis or nodular melanomas 
(e.g., (Schartl et al. 1995; Fernandez and Bowser 2010)). Second, Fernandez and Bowser 
(Fernandez and Bowser 2010) observed that 8 out of 52 non-hybrid males of X. cortezi at one 
field site showed signs of melanoma stemming from Xmrk genes. However, closer 
examination of these fish did not reveal adverse impacts of the neoplasms, and the authors 
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did not note whether the remaining field sites were similarly inspected. Nevertheless, the fact 
that not all fish harbour the Xmrk gene suggests some form of frequency dependent or 
fluctuating habitat selection (see (Fernandez and Bowser 2010) for discussion), indicative of 
antagonistic pleiotropy. 
Inferring and untangling causal factors. In species where cancer epidemiology has been 
quantified, there is almost invariably a hypothesized contributing novel environment 
(Vittecoq et al. 2015; Ujvari et al. 2016a)). However, inferring environmental influence is 
often based on probable or possible cause. For example, Daoust et al. (1991) notes the stark 
contrast in multicentric mesenchymal tumour incidence between samples of White-fronted 
geese (Anser albifrons), (23%, n=30) and three other goose species: Branta canadensis 
(0.9%, n=117), Chen caerulescens caerulescens (0%, n=594), and Chen rossii (0%, n=77). 
The cause (s) of these striking differences, although suggestive of environmental impacts on 
White-fronted geese, would be difficult if not impossible to either retrospectively evaluate, or 
to retest should present-day populations show little or no cancer.  
Indeed, determining contribution and, more specifically, causality in disease and mortality is 
notoriously difficult (Rothman and Greenland 2005). Cancers are no exception, in part 
because one or more etiological agents may be contribute (for certain bivalves, see (Carballal 
et al. 2015)) and interact with one another in a causal web (for humans (Galea et al. 2010)). 
Moreover, cancer may be only one of a myriad of diseases and dysfunctions affecting the 
organism. This means that it will often be difficult to establish the causal and/or contributing 
role of cancer in individual health, reproduction and survival, and by extension, whether 
cancer itself will impact natural selection. Consider the following hypothetical but realistic 
scenario. In studying samples of a population over many generations it is discovered that 
individuals exposed to a toxin show one or more cellular and tissue abnormalities (including 
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cancers) that are statistically associated with mortality risk. Should resistance evolve, will it 
(1) detoxify the chemical, and/or (2) result in the avoidance of habitats where the chemical is 
found, and/or (3) act downstream and suppress cancers and/or other diseases caused by toxin 
exposure? Assuming that a unique set of cancer driver mutations are obtained sequentially, 
different environmental (causal) factors may each differentially be responsible for each driver 
mutation as part of a multistage process. Determining how natural selection proceeds in 
complex situations such as this is largely unexplored. 
The ‘Primacy of Mortalities’. All else being equal, changes in the incidence of factors that 
contribute to mortality over a given age range will (obviously) alter the incidence of other 
factors that act at the same or at later ages. In contrast, changes in the incidence of late acting 
factors are less likely to affect the dynamics of those acting at younger ages. This well known 
demographic effect is potentially important for cancer risks that increase precipitously with 
age (e.g., human prostate cancers). For example, improvements in preventing and treating 
early-onset cardiovascular diseases have not only increased life span, but also appear to have 
shifted deaths to other later-occurring causes, including cancer (e.g., (Davis 1994)). 
Moreover, different diseases show contrasting age-specific patterns in multi-stage 
acceleration (Frank 2004b), suggesting that complex patterns in age-specific cancer risk may 
emerge due to changes in the probabilities of other diseases occurring (e.g., through more 
effective prevention or individual treatment). As discussed in more detail below, many 
cancers observed in captive animals and in humans are an indirect consequence of reducing 
mortality in young and mid-aged individuals through, for example, animal protection in 
households and zoos, and, for humans in particular, improved sanitation and health care. 
  
A framework for novel environmental impacts on cancer 
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Despite biases in quantification and difficulties in ascribing cause, as discussed below, there 
is considerable evidence that novel environments contribute to explaining the high levels of 
present-day cancer in many animal species, and the majority of cancer risk in humans. What 
is currently lacking is a framework for understanding the causal web of how environments 
impact cancer risk. We take first steps towards a more general theory of cancer risk by 
proposing a framework for how environments influence one or more of three distinct 
biological levels (The organism, Within-organism processes, The genome; Figure 2) and how 
this, in turn, leads to cancer (Figure 3). We then illustrate how our framework can be used to 
gain quantitative insights into overall cancer risk in the human population. 
1. The organism: longer life span and larger body size. Most cancers in humans and the few 
other animal species studied in detail are associated with longevity and aging (Campisi 2013; 
de Magalhães 2013). Whereas survival to ages at which cancer is a health threat is probably 
rare in natural habitats (Finch 1990; Kirkwood 2005), modern-day transformations have 
made survival to cancer-prone ages the rule for many species living in protected 
environments, particularly humans.  
Improved survival increases cancer risk in three interactive ways. First, because cancer is a 
multi-stage mutational process, longer life means more time to obtain all necessary mutations 
to produce a cancer and for the cancer to grow, spread, and impact performance and health. 
Second, the aging process itself favours both genomic instability (Vijg and Suh 2013) and the 
likelihood that tissue microenvironmental conditions will be hospitable to the expression of 
deleterious mutations leading to tumour development and invasion (DeGregori 2011; 
DeGregori 2012; Campisi 2013). Third, longer life means more potential exposure to 
environmental factors (e.g., mutagens) that increase the probability of multi-stage 
carcinogenesis obtaining (see Within-organism processes below).  
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One prime example of increases in health and longevity is the confinement of wildlife in 
protected habits (e.g., laboratories, nature reserves, zoos, homes; but see (Clubb and Mason 
2003)). As alluded to above, studies from zoo animals indicate that most species have cancer 
incidences lower than 5% (Effron et al. 1977; Abegglen et al. 2015), though according to the 
data compiled by Abegglen and coworkers (2015) a significant minority (30% or 11/37 
species) exhibit incidences (based on necropsied animals) above 5%. Beyond the reasonable 
hypothesis that many observed cancers in laboratory and captive populations are associated 
with longer life spans compared to field situations, and notwithstanding potential biases due 
to small sample sizes, to the best of our knowledge, many of the cases greater than c. 5% 
lifetime risk reported in the literature can be explained by other novel environmental effects 
as contributing factors, for example, viral infections or the use of chemical contraceptives 
(e.g., (McAloose et al. 2007; Ewald and Swain Ewald 2015) (see also Within-organism 
processes below).  
The life spans of modern humans and their ancestors have increased over time scales of 
millions (Caspari and Lee 2004; Finch 2007), tens of thousands and thousands (Kaplan et al. 
2000; Caspari and Lee 2004; Burger et al. 2012), and hundreds and tens (Fogel 2012; Burger 
et al. 2012; NCD Risk Factor Collaboration (NCD-RisC) 2016) of years. Modern medicine 
promotes longevity (increasing cancer risk), but also lowers cancer mortality at younger ages 
and shifts some cancer effects on health and survival to older ages. The net overall pattern is 
that overall cancer risk in Western society is less than 1% by age 20, about 2% by age 40, and 
less than 10% at 50 (Martincorena and Campbell 2015). These low figures, despite numerous 
mutagenic exposures (e.g., smoking, UV radiation), can be explained both by highly effective 
cancer resistance mechanisms at younger ages, and by the many years typically required to 
complete the multistage process and for the resultant cancer to have health consequences 
(Jones et al. 2008; Yachida et al. 2010). 
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Similar to life span, body mass is expected to correlate with the lifetime number of stem cell 
divisions in the organism, and therefore cancer risk (Peto 1977; Nunney 1999; Noble et al. 
2015). Although body mass itself is associated with life span between species, the 
correlations differ between taxa (Healy et al. 2014), and the within species correlation is more 
complex (Speakman 2005). Indirect evidence for associations between increased body size 
and cancer comes from how improved nutrition and health care have contributed to general 
increases in human stature and life span over recorded history ( ( (Floud et al. 2011), but see 
e.g., (Formicola and Giannecchini 1999) for variation over much longer time spans). Human 
height is correlated with the masses of many tissues and organs, such as the liver, kidneys and 
the heart (Heymsfield et al. 2007). Height is therefore also expected to correlate with the 
number of cell divisions required to establish these organs and maintain their function (Floud 
et al. 2011; Zhao et al. 2011), which in turn is expected to correlate with cancer risk (Albanes 
and Winick 1988; Noble et al. 2015). Limited support for this complex chain of causality 
comes from study of human height (Shors et al. 2001; Green et al. 2011; Kabat et al. 2014; 
Jiang et al. 2015) and the size of certain organs (Silva et al. 2011) correlating with cancer 
risk. 
2. Within-organism processes: disrupted cells, tissues and support systems. Even with the 
establishment of highly effective cancer resistance mechanisms, natural selection is not 
expected to achieve zero risk (see above and, more generally, (Lynch 2012)). Our hypothesis 
is that sufficient perturbations with respect to the native states of environmental variables 
affecting cancer risk will increase the probability of obtaining somatic mutations leading to 
cancer. This may be associated with, for example, injury, disease, or exposure to mutagens 
(e.g., (Grivennikov et al. 2010; Dang 2015)). Gluckman and Hanson (2004) have argued that 
environmental conditions during periconceptual, fetal and infant periods of life can have 
significant impacts on disease risk. However, the implications of these effects for cancers are 
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little understood.  
There are numerous examples in humans and other metazoans of suspected or demonstrated 
associations between environmental impacts on individual physiology and cancer (Newman 
and Smith 2006; McAloose and Newton 2009), such as chemical exposure (Martineau et al. 
2002; Lerebours et al. 2014), contraceptives (Harrenstien et al. 1996), and UV radiation 
(Fernandez et al. 2012; Leiter et al. 2014). Whereas humans often have a causal role in 
cancers stemming from these and other abiotic or physical environmental variables, human 
implication is usually more difficult to demonstrate in the many cancers associated with 
extra- and intra-cellular organisms. Indeed, extra- and intra-cellular organisms are widely 
considered to be a major factor associated with certain cancers in animals and in humans 
(Ewald 2009; McAloose and Newton 2009; zur Hausen 2009; Coffee et al. 2013; Ewald and 
Swain Ewald 2015) (Box 2). This may involve changes to the microbiome (Dalmasso et al. 
2014; Vogtmann and Goedert 2016), but is more usually associated with parasitic infections. 
According to de Martel and colleagues (de Martel et al. 2012) pathogens are estimated to 
account for 16.1% of human cancer globally, with considerable variation between cancer 
types and geographical regions. Evaluating causality between pathogens and cancer is 
challenging, in part because of potential delays between the presence of the parasite and 
cancer detection (Ewald and Swain Ewald 2015). An alternative approach to linking infection 
with cancer is to study temporal correlations in parasite infection dynamics and cancer. 
Examples include the spread of HPV (e.g., (Baseman and Koutsky 2005; Ramqvist and 
Dalianis 2010; Chaturvedi et al. 2011)), HIV (Robbins et al. 2014) and Hepatitis C virus 
(Perz et al. 2006). 
In addition to impacts mediated by the external environment, humans, in particular, influence 
their own cancer risks through certain lifestyle behaviours. These include alcohol 
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consumption, UV exposure, smoking (Irigaray et al. 2007), but also certain foods (Soto and 
Sonnenschein 2010), and lack of physical activity and obesity (Vucenik and Stains 2012). 
Moreover, there is some evidence that other behaviours such as sleep patterns (Blask 2009), 
reproductive biology (Aktipis et al. 2014), and psychological states (Reiche et al. 2004), 
stresses and trauma (Reiche et al. 2004; Antoni et al. 2006) influence cancer risk. 
3. The genome: the emergence of cancer sensitivity genes. Changes to the heritable genome 
can have considerable impacts on cancer. These range from very simple to highly complex 
predispositions (for humans, see (Frank 2004a)). Certain cancers are promoted by 
homozygosity or drift due to genetic bottlenecks, selective breeding, or by founder effects. 
For instance, in humans, founder effects and preferential association within groups may 
favour the persistence of cancer sensitivity genes (de la Chapelle and Wright 1998; Rudan et 
al. 2003; Fackenthal and Olopade 2007).  
In animals, the emergence and persistence of some cancers, in particular transmissible 
cancers (Box 2), may be promoted by low genetic diversity or heritable sensitivity genes 
(Fredrickson 1987; Siddle et al. 2007; Miller et al. 2011; Murchison et al. 2012; Murchison et 
al. 2014; Browning et al. 2014). For example, the Santa Catalina Island fox shows a cancer 
rate of c. 50%, and this elevated level could be explained by some combination of mite 
infections often associated with these cancers, and the accumulation of deleterious mutations 
in this highly inbred, low genetic diversity population (Vickers et al. 2015; Robinson et al. 
2016). Other fox populations on two other of the Channel Islands are also inbred, also subject 
to mite infections, but show no cancer (Vickers et al. 2015). Thus, mites and genetic effects 
may be causal, but additional factors appear necessary to explain cancers on Santa Catalina 
Island only.  
Human-induced population bottlenecks and selective breeding appear to contribute to many 
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cancers in domestic animals (Vail and MacEwen 2000; Dobson 2013). For example, some 
cancers in domestic dogs have a genetic basis, stemming from selective breeding (Dobson 
2013; Karyadi et al. 2013; Davis and Ostrander 2014; Schiffman and Breen 2015). Similarly, 
strong selection for specific traits may increase cancer risk, such as more frequent egg laying 
in farmed chickens leading to increased age-related incidence of ovarian cancer (Johnson et 
al. 2015). Finally, a recent study on Hydra suggests that prolonged breeding in captivity 
fostered the emergence of tumours after approximately 50 asexual generations ( (Domazet-
Lošo et al. 2014); Alexander Klimovich, pers comm), suggestive of epigenetic alterations, 
emerging pleiotropy, or mutation accumulation. 
  
Cancer risk in past and present human populations 
As indicated above, cancer risk in the human population is subject to alterations in all three 
biological levels. Not surprisingly, many if not most of these effects are associated with 
impacts from humans themselves, and in particular extended life spans, environmental 
mutagens, and lifestyle behaviours. These risks (and by extension, their environmental 
drivers) are the basis for the current debate of the relative importance of random mutation and 
environmental drivers in human cancers (Box 3). Here, we take initial steps towards 
understanding the roles of environment in cancer risk by considering some of the general 
features of human life history and demography past and present. In particular, we employ 
information about hunter-gatherers currently and in the recent past to calibrate a 
mathematical model and conduct a sensitivity analysis with the goal of predicting what 
overall cancer risks may have been in our recent and more distant ancestors. 
Estimates vary, but generally indicate expected hunter-gatherer life spans of 30-40 years 
(Gurven et al. 2007). Tuljapurkar and colleagues (2007) used demographic models of men 
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and women to estimate the relative force of selection (Glossary) as a function of age. Their 
results indicate that the fitness effect of a mutant allele expressed beyond 40 years of age is 
20% of what it would be if it were expressed beyond 20 years of age. Selection on an 
individual at 50 and 60 years of age is 5% and 1%, respectively, of selection on a 20 year old. 
If this applies generally to pre-modern humans, then it suggests that there would have been 
selection against germline cancer sensitivity, but with a pronounced decline for those cancers 
with health effects after approximately 40 years of age. Supporting this prediction, modern 
day age-specific cancer risk (e.g. (Howlader et al. 2013)) recapitulates the inverse of the 
predicted force of selection in early Homo sapiens (Tuljapurkar et al. 2007) and in modern 
hunter-gatherers (Lee 2003). 
Additional evidence for the hypothesis of less cancer in our recent and distant ancestors 
comes from mortality data in hunter-gatherer groups prior to outside contact. Data from pre-
contact (before 1960) Hiwi indicate low levels (4/86 or 5% of young and older adult deaths) 
of “other organic/pathological” causes of mortality (including cancers), whereas post-contact 
was considerably higher (26/69 or 38%) (Hill et al. 2007). However, it is not known with 
certainty how cancers may have contributed to these or other mortalities. Similar assessments 
(lower life expectancy and lower risks for certain cancers compared to Western society) hold 
for the Tsimané Amerindians (excluding deaths from unknown causes, 1.3% (16/1276) of 
deaths attributable to cancers for all ages, and 7.8% (7/90) for individuals 60 years old or 
greater) (Gurven et al. 2007), and Inuits (Wilkins et al. 2008; Boysen et al. 2008) for which 
rapid social and environmental changes may explain why the incidence of many cancers has 
recently increased (Boysen et al. 2008; Young et al. 2016), whereas high incidence, endemic 
nasopharyngeal cancers appear to be linked to infectious agents (Friborg and Melbye 2008). 
A mathematical model of cancer risk in humans 
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To examine the relationship between longevity and cancer risk, we use a simple mathematical 
model (Supplementary methods) that accounts for the probability of acquiring cancer for the 
first time, the mortality rate due to cancer, and the rate of background mortality (that is, death 
from causes other than cancer). 
However, in reality, populations vary in cancer risk and cancer death rate, as well as 
background mortality. Based on modern US life expectancy and cancer incidence curves, our 
model predicts, as expected, a lifetime cancer risk of approximately 40% (Fig. 4C). A 
population that is identical except that it has 30% lower cancer incidence in adults is 
predicted to have approximately 30% lower lifetime risk of cancer (Fig. 4C). In pre-modern 
humans, the model estimates a lifetime cancer risk between 0.6% and 10% (for those alive 
and cancer-free at age 5). The higher estimate (Fig. 4C) assumes that background mortality in 
pre-modern humans was similar to what is observed in modern hunter-gatherers (Gurven et 
al. 2007), and that adult cancer risk per year was 30% lower in pre-modern humans than in 
the modern US population (based on epidemiological studies that estimate 30%-50% of risk 
in modern Western populations is attributable to lifestyle (Doll and Peto 1981; Parkin et al. 
2011; Song and Giovannucci 2016); see also Supplementary Fig. 1)). The lower estimate 
assumes a much higher background mortality rate deduced from prehistoric skeletal remains 
(Gage 1998) – which most likely overestimates adult mortality (O’Connell et al. 1999) – and 
assumes that cancer risk per year was 80% lower than in the US currently (due to changes in 
both environment and stature). The model results indicate that most of the difference in 
lifetime cancer risk between pre-modern humans and the modern US population is due to 
lower background mortality in the latter, which enables more individuals to attain the 
advanced ages at which cancer risk is substantially increased. If modern US cancer incidence 
applied to modern-day hunter gatherers and to Sweden in 1861, then lifetime cancer risks in 
the latter populations would be 13% and 24%, respectively (in individuals alive and cancer-
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free at age 5, assuming the same stature and environmental contributors as in the US 
currently). 
Contrasting patterns emerge when we examine cancer risk over the age range 5-40 years old, 
which is when the force of selection is expected to be strongest (Fig. 4A). The model 
indicates that cancer risk by 40 years old was between 0.4% and 1% in pre-modern humans, 
whereas it is c. 2% currently in the US population (Fig. 4D). Most of this difference is 
predicted to be due to increased environmental forcing in the modern population. In 
particular, once life expectancy reaches 75 years, the background mortality rate before age 40 
is already very low. Therefore further reductions in background mortality (which will 
increase life expectancy beyond 75 years) are predicted to have almost no effect on cancer 
risk by 40 years old (Fig. 4D), whereas not surprisingly they have a dramatic effect on cancer 
risk over a lifetime (Fig. 4C). 
Note that these results for the human population concern the lifetime risk of acquiring cancer, 
irrespective of possible effects on health or survival. Thus, the age-specific incidence data 
used in the model is likely to overestimate actual cancer risks, in part due to advances in 
detecting cancers, many of which have no subsequent effects on health or survival. In 
populations with high background mortality rates (e.g., ancient hunter-gatherers), cancer 
would less often have negative consequences due to the primacy of mortalities. 
 
Discussion 
We argue that elevated cancer risks across the tree of life – particularly observations of 
greater than c. 5% lifetime risk – are largely attributable to novel environments, that is 
deviations in certain environmental conditions experienced over evolutionary time scales in 
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native habitats (Fig. 1). This is not to say that resistance to certain cancers in certain species 
does not continue to evolve, but rather that over ecologically relevant time spans of less than 
a few generations, environmental drivers and not evolutionary responses dominate variation 
in cancer epidemiology. We stress that c. 5% is a proposed benchmark, based on our 
literature survey showing no indiscutable examples of cancer beyond this level that cannot be 
explained by influences of novel environments, and our case study of ancient humans 
suggestive of similar levels. Inversely, the benchmark of c. 5% is a prediction of the limits of 
evolution in limiting cancer risks across life, and we expect that the actual figure may be 
much lower for many species. Supporting this, Abegglen et al. (2015) found that 51% of the 
captive species in their data set showed no cancer. Although these cases may be explained by 
e.g., small sample sizes--taken at face value they suggest that baseline levels in native 
habitats are likely to be extremely low as well. First-principles theory would be valuable to 
test our prediction as a general limit across species, and to discover the limits of selection in 
preventing cancer across different species ecologies. 
Our proposal that anthropogenic influences explain much of the novel environmental 
variation responsible for present-day cancer risks, is in line with previous study suggesting 
that cancer was of lower importance in free-living animal populations and in humans in the 
(distant) past (e.g., (Capasso 2005; David and Zimmerman 2010)). We contend, nevertheless, 
that cancer has been and still is occasionally important for certain populations in the wild 
that are relatively untouched by human activity. Arguably the most prevalent contributors are 
parasitic infections (Ewald 2009; Ewald and Swain Ewald 2015), but more research is needed 
to evaluate the extent to which these deviate from evolutionary norms (Fig. 1), and if so, the 
potential indirect causal role of humans (e.g., contaminants the increase parasitic infection 
and cancer). 
Although environmental impacts on cancer epidemiology are attracting increased interest, the 
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relevance for ecological and evolutionary dynamics remains underexplored. Similar to certain 
parasites, transmissible cancers and cancers associated with parasitic infections can have 
significant population and evolutionary impacts (Box 2), and possibly epidemic-like 
behaviour (McCallum et al. 2009; Ramqvist and Dalianis 2010). Epidemic-like phenomena 
could also occur in species vulnerable to endogenous cancers, but aside from correlations 
between environmental factors and cancer incidence, the implications for species ecology is 
unknown. The implications of cancer epidemiology for species ecology will be challenging to 
study, given the typical delays between environmental causes and the effect of the disease on 
individual performance and survival (e.g., (Ewald and Swain Ewald 2015; Lair et al. 2015)).  
Beyond the obvious need for more studies explaining cancer risks in free-living species, both 
in near-pristine systems and in those perturbed either naturally or by human activity, several 
important questions merit attention. (1) To what extent are cancers distinct from infectious 
and noninfectious diseases in how they are affected by environments (Eisenberg et al. 2007) 
and, inversely, in how they affect species ecology and evolution (Vittecoq et al. 2013; Ujvari 
et al. 2016a)? (2) For the many cancers associated with viral or parasitic infections, will 
selection for resistance be directed at the parasite, or at the subsequent induction of cancer? Is 
the epidemiology of cancer-associated parasites distinct from other parasitic organisms? (3) 
Can we detect contemporary signals of selection on cancer genes (either directly or linked to 
other traits under selection) due to altered environments? (4) We actually do not know cancer 
risks as a function of environmental conditions (Fig. 1) for any species or cancer type. How 
sensitive are different cancer types on the basis of the tissues they affect to different 
environmental drivers? (5) Our study considered the risk of any cancer affecting individual 
performance, health, survival and fitness. How do the risk levels of different cancer types 
(e.g., cancer cell phenotype; tissues or organs affected) vary with environments and 
phylogenetically across species? (6) Are there any phylogenetic signals of cancer resistance 
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evolution and natural cancer risk? That is, to what extent do novel genes associated with 
cancer risk appear in species lineages, or rather is most evolution due to modifications to 
existing genes (e.g., copy number (Abegglen et al. 2015))? And finally, (7) to what extent can 
cancer be employed as an indicator of more general environmental impacts, such as global 
climate change, species invasions or infectious disease epidemics? Linking specific cancers 
with a single or small number of causal factors could be useful in certain wildlife 
conservation efforts (McAloose and Newton 2009) and in cancer prevention in the human 
population (Box 3). 
In conclusion, the framework presented here focuses on how deviations from native 
environmental conditions increase cancer risk at (1) the whole-organism level, by enabling 
larger body size and longer life span, (2) the within-organism level, by disrupting intra-
individual physiology and (3) the germline level, by altering genomes and cancer 
sensitivity[2]. Supporting the generality of this approach, each of these three levels can be 
linked to more distal contributions of species ecology (e.g., environmental change leads to 
heightened susceptibility to a pathogen associated with cancer, or to population contraction 
and a genetic bottleneck; the removal of a predator results in longer life spans), and to the 
more proximal process of multistage carcinogenesis (the probability of which depends on 
lifetime numbers of stem cell divisions and mutation rates). Nevertheless, given the 
complexity of the causal network proposed here (Fig. 3), testing predictions (Box 4) and 
dissecting impacts of the various contributors to cancer will be challenging, requiring 
theoretical, comparative and experimental approaches. For example, more rigorous tests of 
the effects of captivity on cancer in zoo animals (Ratcliffe 1933), or proposals that reductions 
in predation or parasite pressure should result in increased cancer risk (Vittecoq et al. 2013), 
would require contrasts with data from natural habitats and communities with 
predators/parasites, respectively. For some model species, this could be accomplished with 
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the employment of field enclosures to monitor all individuals and control species composition 
(Legrand et al. 2012). 
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Footnotes 
[1] The most notable exception is transmissible facial tumours in Tasmanian devils (e.g., (McCallum et al. 
2009; Hollings et al. 2016; Epstein et al. 2016)). However, transmissible cancers differ importantly from 
endogenously emerging cancers, in that the population and evolutionary dynamics of the former are more akin 
to certain infectious diseases. 
[2] Evidently, environments approaching a species’ native conditions will result in lowered overall cancer risk. 
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Glossary 
Antagonistic pleiotropy. Expression of a single gene affecting two or more phenotypic 
traits, where at least one trait is beneficial to fitness, and another trait has negative fitness 
consequences. 
Cancer driver mutations. Epigenetic alterations or mutations to key genes that result in the 
Hallmarks of Cancer (Hanahan and Weinberg 2000; Hanahan and Weinberg 2011), including 
unchecked cellular proliferation, tissue invasion and metastasis. In addition to those 
necessary for the Hallmarks of Cancer, other driver mutations may increase the selective 
growth advantage of cancer subclones resulting in accelerated disease spread (Bozic et al. 
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2010) (but see (Sottoriva et al. 2015)). 
Cancer risk. The probability over an individual’s lifetime of cancer emerging and having 
performance, health, survival or reproduction consequences.  
Cellular cheating. Achieving one or more of the Hallmarks of Cancer, resulting in 
deregulation of proliferation inhibition, cell death, division of labour, resource allocation and 
extracellular environment maintenance (Aktipis et al. 2015). 
Comparative oncology. The study of cancer defences and carcinogenesis between species, 
individuals within a species, or between tissues within individuals. 
Force of selection. The fitness of an allele expressed at age x, measured as remaining 
fecundity and contributions (e.g., resource transfers) to the survival and fecundities of close 
kin. 
Invasive carcinoma. A growing population of epithelial cells that exhibit all of the 
Hallmarks of Cancer (Hanahan and Weinberg 2000; Hanahan and Weinberg 2011), infiltrate 
or destroy surrounding tissue, and possibly metastasize. 
Microenvironment. The immediate environment of a cell, including other cells, the vascular 
system, nutrients, immune factors, and chemical signals. 
Multistage theory of carcinogenesis. The theory that cancers proceed through successive 
stages, corresponding to one or more mutations (or epigenetic alterations) activating 
oncogenes and disabling tumour suppressor genes (Armitage and Doll 1954; Frank 2010). 
Some of these mutations may be inherited (Frank 2004a), increasing the risk of certain cancer 
types obtaining . 
Novel environment. The full set of environmental conditions, including those stemming 
from behaviour and ecology, that tend to differ from the conditions under which a species 
evolved, and (in the context of this study) which result in a significant effect on cancer risk 
(Figure 1). Novel environments can be either quantitative (e.g., increased temperatures, 
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increased caloric intake), or both quantitative and qualitative (e.g., pollutants, infectious 
disease, selective breeding). They may also be distal in causation, for example life in 
captivity, healthcare, habitat restriction leading to bottlenecks and inbreeding. We 
hypothesize that novel environments will usually increase overall cancer risk, but it is 
possible that some cancers will decrease (e.g., the invasion of a generalist predator that tends 
to kill older individuals before cancer typically obtains). 
Peto’s paradox. The empirical observation that neither species longevity nor body size 
correlates with cancer risk. The same observation has been identified for tissue families 
within organisms (Noble et al. 2015). 
  
Figure 1 
Figure 2 
Figure 3 
Figure 4 
 
Figure Legends 
Figure 1. Schematic representation of how a novel environmental variable is associated 
with increases in cancer risk above levels established by long-term evolution. The long-
term exposure to an environmental variable (e.g., UV radiation) (black solid line) is expected 
to select for adaptations (see Introduction in main text) that form a norm of reaction in cancer 
risk (red line) across the distribution of the environmental variable. Novel environments shift 
the frequency distribution of the environmental variable (black dashed line) and associated 
cancer risks. Shaded red area around mean risk line either indicates variability among 
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individuals within a population, or between populations of a given species. Note that novel 
environments may result in decreases in cancer risk, as for example, following the invasion 
of a predator or parasite, that shifts species demography to younger (less cancer prone) ages. 
Figure 2. Hypothetical effects on cancer risk of variation in The Organism, Within-
Organism, and The Genome. Specific abiotic and biotic environment variables (including 
lifestyle behaviours) will alter one or more of these biological levels and in so doing, increase 
cancer beyond baseline risks associated with environments experienced over evolutionary 
time (“native” environments) (see Fig. 1). Whereas we expect interactions between whole 
organism and within-organism effects (left panel) on cancer risk, the interactive effects of 
changes to genomes (right panel) will depend, in part, on whether genetic effects selectively 
increase cancer risk in young individuals (e.g., mutations in RB and retinoblastoma in 
humans), or rather, are (partially) age related (e.g., BRCA1 mutations and breast cancer in 
humans). 
Figure 3. A conceptual framework for how environmental factors influence cancer risk 
over ecological and evolutionary timescales. Intrinsic and environmental/behavioural 
factors (green boxes) ultimately determine cancer risk (red boxes) through their effects on the 
proximate mechanism of somatic evolution (blue boxes). In general, a population of stable 
size in a stable environment is expected to evolve low cancer risk, because cancer-affected 
individuals have lower fitness. Environmental change or variation (yellow boxes) can 
increase cancer risk if it outpaces organismal evolution. Within-species variation in cancer 
risk results from genetic diversity, environmental heterogeneity, and from stochasticity in the 
mutational process (“bad luck”; see also Box 3). 
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Figure 4. Relationship between longevity and cancer risk in humans, based on a 
mathematical model using empirical data. (A) Relative force of selection (red line, 
qualitative approximation based on Lee (Lee 2003); for illustrative purposes; not used in the 
model) and relative risk of acquiring cancer for the first time (blue line, used as model input, 
estimated using the DevCan software package (Fay 2004; DevCan: Probability of Developing 
or Dying of Cancer Software 2005), based on US data for 2010-2012). (B) Survivorship 
curves generated by the model (thin lines), with empirical curves for hunter-gatherers, 
Sweden in 1861, and the US in 2011 (thick lines) for comparison. Mortality in children less 
than 5 years old is excluded so as to better reflect typical life expectancy among individuals 
who are at substantial risk of cancer. Model results are shown for low cancer risk (left panel, 
using as input the US cancer incidence curve rescaled by 0.4 for adults) and high cancer risk 
(right panel, using as input the US cancer incidence curve). In both cases, the death rate of 
individuals with cancer in the model is assumed to be 0.1 per year. (C) Lifetime cancer risk 
(for those alive and cancer-free at age 5) versus life expectancy at age 5, according to the 
model. Each lifetime risk curve shows the effect of varying the parameters of background 
mortality, such that the survivorship curve varies within a family of curves resembling those 
shown in the previous panel. Crosses mark model predictions for the modern US population; 
a population identical to the modern US population except that the incidence of cancer per 
year is 30% lower in adults; and a population with the background mortality of hunter-
gatherers and with 30% lower incidence of cancer per year in adults, which is assumed to 
provide an upper bound for cancer risk in pre-modern humans. A 30% difference in cancer 
incidence can be accounted for by lifestyle factors, or by a difference in stature of 
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approximately 19 cm (Supplementary methods). (D) Cancer risk by age 40 (for those alive 
and cancer-free at age 5) versus life expectancy at age 5, according to the model. Crosses are 
as in the previous panel. When cancer incidence and the cancer death rate remain constant, 
cancer risk by age 40 is positively correlated with life expectancy. This is because higher life 
expectancy corresponds to less background mortality, which results in more individuals being 
alive and susceptible to cancer. 
 
Box 1. Relative contributions of life span and body mass to cancer risk 
The multistage theory of carcinogenesis as envisaged by Armitage and Doll (1954) posits that 
several independent mutations are typically required to initiate cancer. This process implies 
that, all else being equal, the more stem cell divisions occurring over a lifetime, the higher the 
probability of a given cancer being obtained (Albanes and Winick 1988), since cells are most 
vulnerable to mutation during the cell cycle (Cairns 2002; Branzei and Foiani 2005). The 
lifetime number of stem cell divisions (and therefore cancer risk) is expected to correlate with 
stem cell number (body size), stem cell division rate, and life span (Nunney 1999; Noble et 
al. 2015). Focusing on body size and life span, theory predicts that the former should have a 
smaller effect on cancer risk than the latter (Nunney 1999). To see this, consider a very 
simple multi-stage model for cancer risk, R 
 TO BE ADDED   (1) 
where s is the number of stem cells, u is the mutation rate at any one of M genes necessary 
for cancer, and d is the number of divisions per stem cell over a lifetime. Rob: other 
assumptions? This simple model assumes that ud < 1. Interestingly, these cellular processes 
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can be reinterpreted as life history traits, whereby s correlates with body mass and d with life 
span. To see the difference in the relative importance of body size (s) and life span (d), 
consider a cancer requiring three mutations (M=3) (Tomasetti et al. 2015). Here, increasing d 
by a factor of 10 changes R as much as multiplying s by a factor of 1000. 
Equation 1 and related formulae (e.g., (Calabrese and Shibata 2010)) characterize R as 
cellular transformation to invasive carcinoma (Glossary), and not the related definition 
employed in our study, the added risk of subsequent effects (e.g., tissue invasion and 
metastasis) on performance or health. A more complete model would incorporate the 
possibility that larger body sizes require more time for cancer foci to have impacts on 
individual performance or health. Moreover, whether modelling cancer emergence only, or 
both emergence and progression, Equation 1 neglects age-related changes in parameters, 
which has been hypothesized to explain differences in cancers typically occurring before and 
during reproduction ages with those usually associated with the aging process (e.g., (Rozhok 
and DeGregori 2016)). 
  
Box 2. Cancer and parasites 
Although cancer cells are comparable to some parasitic organisms in that grow and may 
spread and multiply within the host, there is one fundamental difference: unlike free-living 
parasites, cancer emerges from self, and is not transmitted between individual hosts (but see 
exceptions below). Sporadic somatic cancer is therefore an evolutionary dead end. Cancer 
genes, however, can evolve (and be positively selected (Crespi and Summers 2006)) beyond 
the host individual as vertically transmitted allelic variants within the genome. Evolutionary 
theory predicts that selection on vertically transmitted parasites typically results in lowered 
virulence (Frank 1996). Virulence in the context of cancer genes (i.e., probability of cancer 
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expression, rates of tumour progression and metastasis) would reduce the survival and 
reproduction of hosts, resulting in purifying selection on such genes and/or positive selection 
on other genes contributing to cancer suppression. Another possibility, similar to certain 
parasites (Michalakis et al. 1992)), is that cancer is antagonistically pleiotropic on positively 
genes (Crespi and Summers 2006) (see also discussion in main text in section on Challenges 
to how we perceive and quantify cancer). 
Transmissible cancers share features with certain horizontally transmitted parasites 
(Ostrander et al. 2016; Ujvari et al. 2016b), including intra-specific (Murgia et al. 2006; 
Siddle et al. 2007; Metzger et al. 2015) and interspecific (Metzger et al. 2016) infection. 
Transmissible cancers are also similar to some parasites in that emergence and spread may 
depend on environmental conditions (Lafferty and Kuris 1999). For cancers, this includes low 
genetic diversity in Tasmanian devils and in dogs (Murgia et al. 2006; Siddle et al. 2007; 
Miller et al. 2011), and pollutants in molluscs (J. Sherry, pers comm: (St-Jean et al. 2005; 
Muttray et al. 2012) but see (Barber 2004) for both examples and counterexamples)). 
There is also recent evidence that (similar to many parasites) canine transmissible cancers 
may have evolved via recombination (Strakova et al. 2016). However, it is not known for this 
or other transmissible cancers whether evolutionary rates are similar to parasitic species with 
comparable life cycles and life histories. Although not experimentally demonstrated, the low 
virulence of transmissible cancers in dogs (evolved over thousands of years) and the high 
virulence of facial tumours in Tasmanian devils (tens of years) ( ( (Murgia et al. 2006; Siddle 
and Kaufman 2013); but see (Epstein et al. 2016)) are consistent with predictions of the 
evolutionary attenuation of initially high virulence (Frank 1996; Wirth et al. 2006; Ashby and 
Boots 2015). 
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Box 3: Cancer and “bad luck” in humans 
Tomasetti and Vogelstein (Tomasetti and Vogelstein 2015) compiled data on 31 cancer types 
in humans to assess the relative contributions of a random factor (“bad luck”) and 
environmental and inherited factors to cancer incidence. They proposed that the random 
factor should correlate with the total lifetime number of stem cell divisions per tissue or 
organ type, assuming that cancer-causing mutations have a fixed probability of emerging per 
stem cell division. Stem cells divide during ontogeny and in tissue repair, the latter being 
associated with, for example, injury, parasitism, mutagenic exposure, cellular aging and 
cellular diseases other than cancer. Their analysis uncovered a strong positive association 
between cancer incidence and the lifetime number of stem cell divisions, which they 
interpreted as indicating that random mutations due to replication and repair errors (“bad 
luck”) explain much of the variance in risk among cancer types in humans. In a subsequent 
study, Wu et al. (Wu et al. 2016) claimed, on the contrary, that extrinsic environments play a 
much larger role in human cancer risk than does “bad luck”. Such contrasting results 
highlight the challenges in untangling the effects of intrinsic processes and extrinsic 
environments on cancer risk (Noble et al. 2015; Noble et al. 2016). In the more complete 
framework proposed here, environmental and intrinsic factors interactively determine the 
parameters of somatic evolution, which, in turn, contributes to cancer risk (Fig. 2). Some of 
these factors (e.g., those due to lifestyle) are preventable, and account for many, possibly the 
majority of present-day human cancers (Doll and Peto 1981; Schottenfeld et al. 2013; White 
et al. 2014; Colditz and Sutcliffe 2016; Song and Giovannucci 2016), whereas others (e.g., 
inherited cancer risks, old age) magnify within-organism disruption (shape of risk isoclines in 
Fig. 2), and together with particular risks of certain cancers across ethnic groups and 
geographical regions (Vineis and Wild 2014), should be taken into consideration in 
determining risk status. 
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Box 4: Predictions 
Below, we list several predictions based on one or more of the following: Equation 1 (Box 1), 
interpretations of how environment influences cancer risk (Fig. 3), empirical examples (main 
text), and the parameterised model for the human population (Supp. info.). 
1. Populations with greater than c. 5% overall cancer risk are notably impacted by novel 
environments. Environmental drivers—not necessarily stemming from human influences—
include parasites, increased senescence following predator extinction, genetic bottlenecks 
(e.g., island species), and founder effects. All else being equal, for taxonomic or 
interpopulation comparisons, reduced performance due to physiological aging (or 
senescence) should correlate with increased lifetime cancer risks in either native or novel 
environments. 
2. The effect of disrupted bodies on cancer risk relative to the baseline risk is larger when life 
expectancy is lower, but the absolute effect is greater in longer-lived populations. For 
example, if the lifetime cancer risk in the native environment is 1% and in the novel 
environment is 1.3%, then the relative change is a 30% increase, and the absolute change is a 
0.3 percentage points increase. Therefore, the effects of disrupted bodies are more likely to be 
observed in species with longer life spans and senescence.  
3. Marginal increases in survival, especially post-reproduction, will have a greater marginal 
impact on cancer risk than marginal increases in body size (see also (Frank 2004c)). 
4. To the extent that cancer reduces the performance or survival of senescing individuals, it 
will (not surprisingly) have less impact on the ecology and evolution of the species. Notable 
exceptions are social species in which older individuals play important roles in group 
dynamics (e.g. many primates). 
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5. Based on a first approximation of linear marginal effects of environmental change on each 
parameter in Eqn. 1, Box 1, and the realistic assumption that most cancers require two or 
more mutations (in humans, where this is best understood (Knudson 2001)), we predict that 
environmental impacts on mutation rate (u) or life span (as a proxy for total stem cell 
divisions per lineage, d) will have exponential implications for cancer risk, whereas the 
influence on body size (as a proxy for total number of stem cells s) will be linear. Whether 
environmental perturbations alter the number of mutations required for a cancer to obtain (M) 
is an open question, but if they do, then their effects may be highly non-linear depending on 
the baseline level of M. 
6. Similar to prediction 5, the relation between life span d and body size s: (Speakman 2005) 
leads to the prediction that when selection for larger body size coevolves with cancer 
resistance (Kokko and Hochberg 2015) so as to maintain a constant risk level, (correlated) 
longer life spans will have a greater marginal effect than evolving larger body size alone, but 
only when M > 5. In contrast, for M < 5, body size will have a greater marginal effect than 
correlated changes in life span. Note that this prediction assumes that coevolution will follow 
the same relation as identified by Speakman (2005) for interspecific comparisons. 
7. Responses to selection of environmentally-driven cancers will frequently be slow or 
insignificant due to the long generation times of many vulnerable species, the low selective 
value of older individuals typically impacted by cancers, the probabilistic nature of 
tumorigenesis, the complexity of the genetic basis for cancer sensitivity, and/or the low 
population frequency of sensitivity genes. 
8. Species with few and/or weak mechanisms of cancer resistance (which nevertheless are 
effective in native environments; Fig. 1), are particularly vulnerable to cancers stemming 
from environmental vagaries. 
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9. Increasing US life expectancy by one year (through decreases in background mortality) is 
predicted to increase lifetime cancer risk by c. 1%.  
 
 
